As reported recently in the Los Angeles Business Journal, Los Angeles metropolitan area-based DXTerity Diagnostics, founded in 2006, has grown to $10 million in revenue. The diagnostic venture purports to hold $150 million in contracts for blood tests for radiation, a gene-based test that can triage residents in the aftermath of a nuclear attack.
The company has developed other blood tests that can help diagnose and manage autoimmune diseases such as lupus, multiple sclerosis and rheumatoid arthritis. As reported in the local business journal, DxTerity signed agreements with two undisclosed pharmaceutical companies in July and October to employ its gene-based tests in two large clinical studies to determine how lupus and multiple sclerosis patients respond to the treatment.
Source: Los Angeles Business Journal